BPC-157 vs PEG-MGF
Extensively Studied vs limited
synergistic Complementary mechanisms. BPC-157 promotes angiogenesis; PEG-MGF activates satellite cells. Popular recovery stack.
Molecular Data
BPC-157 PEG-MGF
Weight 1,419.53 Da ~2,888 Da
Half-life <30 minutes 48-72 hours (via PEGylation)
Chain 15 amino acids 24 amino acids
Type Pentadecapeptide IGF-1Ec splice variant C-terminal peptide
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
PEG-MGF
01 Extended half-life through PEGylation
02 Satellite cell activation for muscle repair
03 Recovery support following mechanical stress
04 Potential neuroprotection against oxidative stress
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
PEG-MGF
200-400mcg per injection / 2-3x weekly, ideally post-workout
General Recovery 200mcg 2-3x weekly
Targeted Muscle Recovery 200-400mcg Post-workout, 2-3x weekly
Injury Recovery 200-400mcg 2-3x weekly
Conservative Protocol 100-200mcg 2x weekly
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
PEG-MGF
Injection site soreness
Mild fatigue
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Any history of cancer or neoplastic disease
Pregnancy or breastfeeding
Uncontrolled diabetes or severe hyperglycemia
Research Evidence
BPC-157 PEG-MGF
Status Extensively Studied limited
References 6 studies 3 studies
Latest January 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.